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-Linolenic acid supplementation for prophylaxis of atopic dermatitis—a
randomized controlled trial in infants at high familial risk1–3
Christel JAW van Gool, Carel Thijs, Charles JM Henquet, Adriana C van Houwelingen, Pieter C Dagnelie, Jaap Schrander,
Paul PCA Menheere, and Piet A van den Brandt
ABSTRACT
Background: Studies suggest that low concentrations of n–6
long-chain polyenes in early life are correlated to atopic disease in
later life.
Objective: The purpose of the study was to investigate the possi-
ble preventive effect of -linolenic acid (GLA) supplementation
on the development of atopic dermatitis in infants at risk.
Design: In a double-blind, randomized, placebo-controlled trial,
formula-fed infants (n = 118) with a maternal history of atopic
disease received borage oil supplement (containing 100 mg GLA)
or sunflower oil supplement as a placebo daily for the first 6 mo
of life. Main outcome measures were the incidence of atopic der-
matitis in the first year of life (by UK Working Party criteria), the
severity of atopic dermatitis (SCORing Atopic Dermatitis; SCO-
RAD), and the total serum immunoglobulin E (IgE) concentration
at the age of 1 y.
Results: The intention-to-treat analysis showed a favorable trend
for severity of atopic dermatitis associated with GLA supple-
mentation (x– ± SD SCORAD: 6.32 ± 5.32) in the GLA-supple-
mented group as compared with 8.28 ± 6.54 in the placebo group
(P = 0.09; P = 0.06 after adjustment for total serum IgE at base-
line, age 1 wk), but no significant effects on the other atopic out-
comes. The increase in GLA concentrations in plasma phospho-
lipids between baseline and 3 mo was negatively associated with
the severity of atopic dermatitis at 1 y (Spearman’s correlation
coefficient = 0.233, P = 0.013). There was no significant effect
on total serum IgE concentration.
Conclusion: Early supplementation with GLA in children at high
familial risk does not prevent the expression of atopy as reflected
by total serum IgE, but it tends to alleviate the severity of atopic
dermatitis in later infancy in these children. Am J Clin Nutr
2003;77:943–51.
KEY WORDS Fatty acids, essential fatty acids, atopy, atopic
dermatitis, children, supplementation
INTRODUCTION
Essential fatty acids (EFAs) are believed to be involved in the
etiology of atopic disease (1). In the n6 EFA series, linoleic acid
(LA, 18:2n6), derived from food, is subsequently converted into
-linolenic acid (GLA, 18:3n6) and longer-chain polyenes
(LCPs) such as dihomo--linolenic acid (DGLA, 20:3n6) and
arachidonic acid (AA, 20:4n6). Although LCPs of the n3 EFA
series can be derived from -linolenic acid (ALA, 18:3n3), the
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major source of n3 LCPs is food. As early as 1937, lower con-
centrations of AA were reported in the serum of children with
atopic dermatitis (AD; 2). More recent studies have shown higher
concentrations of LA and substantially lower concentrations of its
LCPs in the blood of these patients (3–5). In newborn infants with
a family history of atopic disease, lower n6 LCP concentrations
in umbilical cord blood were found to precede the development
of AD (6). One suggested explanation for these findings was a
reduced conversion of LA into GLA and subsequent LCPs, possi-
bly as a result of impaired activity of the enzyme linoleoyl-CoA
desaturase (6-desaturase; EC 1.14.19.3) (3, 7). Other studies
showed that breast milk from mothers whose infants subsequently
developed AD contained less n6 LCP than did milk from moth-
ers whose infants remained unaffected (8, 9). Unlike breast milk,
infant formulas until recently contained only LA and ALA as
EFAs. Only lately are some brands of formula being enriched with
LCPs, including GLA.
Intervention studies with GLA supplementation in patients with
AD have shown inconsistent results. Most trials were carried out
in a mixed population of adults and children; only 2 trials were
restricted to children (10, 11). All of these trials aimed at decreas-
ing the severity of existing eczema; no preventive trials have been
conducted.
A possible role of GLA in the prevention of atopy in early life
has been postulated by Melnik and Plewig (12), on the basis of
the following 3 observations. First, body composition with respect
to EFAs in newborn infants is entirely dependent on intrauterine
supply and the subsequent choice of breast- or bottle-feeding (13).
Second, mothers of atopic infants have lower concentrations of
n6 LCP in their breast milk than do mothers of nonatopic infants
(9). Third, infants who have atopic symptoms at the age of 1 y
have consistently and significantly lower mean concentrations of
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TABLE 1
Fatty acid profiles of verum (borage oil) and placebo supplements1
Verum Placebo
SFA (% by wt of total fatty acids)
14:0 0.1 0.1
16:0 10.7 5.8
18:0 3.8 3.9
20:0 0.2 0.3
22:0 0.2 0.7
Total 15.0 10.8
MUFA (% by wt of total fatty acids)
18:1n9 15.4 50.7
20:1n9 4.0 0.3
22:1n9 2.7 0.0
Total 22.1 51.0
PUFA (% by wt of total fatty acids)
18:2n6, LA 36.8 36.6
18:3n6, GLA 23.1 0.0
18:3n3, ALA 0.2 0.2
Total 60.1 36.8
Other or unknown (% by wt of total fatty acids) 2.8 1.4
Total 100 100
1 SFA, saturated fatty acid; MUFA, monounsaturated fatty acid; PUFA,
polyunsaturated fatty acid.
n6 LCPs in umbilical cord blood and in serum at 1 and 3 mo of
age than do infants who remain unaffected (6). Prostaglandins
derived from n6 LCPs are thought to play a role in the matura-
tion of the immune system (12). Because the conversion of LA to
GLA is thought to be the rate-limiting step in the total chain of
conversions (14), supplementation with GLA in infancy might
compensate for the lower n6 LCP concentrations and prevent
atopy or decrease its severity in infants, especially if the mother
has an atopic constitution. The purpose of the present study was
to investigate whether GLA supplementation protects against the
development of atopy in high-risk, formula-fed infants.
SUBJECTS AND METHODS
Study design and population
The present study was a double-blind, randomized, placebo-
controlled trial in infants at high risk for AD. It is part of a larger
study of EFAs and atopy, called the EFAtop study. Subjects eligi-
ble for the study were atopic pregnant women and their infants
born during the study period. They were recruited between Octo-
ber 1997 and April 2000 by midwives and via advertisements in
local newspapers in the provinces of Limburg and Noord-Brabant,
Netherlands. The atopic status of both parents of each infant was
assessed with the use of a validated telephone questionnaire.
Inclusion criteria for atopic mothers were a history of allergic
asthma or allergic rhinoconjunctivitis related to aeroallergen expo-
sure, atopic dermatitis, a positive allergen test, or improvement of
asthma or rhinoconjunctivitis with the use of antihistamine or anti-
asthma drugs. Exclusion criteria were diabetes treated with med-
ication or diet or both, preeclampsia, and metabolic disease.
Infants were born between December 1997 and May 2000.
Inclusion criteria for the infants were gestational age of ≥ 38 wk,
birth weight > 2500 g, an uncomplicated perinatal period, and
exclusive formula-feeding from 2 wk of age. All data were col-
lected at the participants’ homes except for the final visit when the
infant was aged 1 y, which took place at the University Hospital
Maastricht. The study was approved by the Medical Ethics Com-
mittee of the University Hospital Maastricht, and written informed
consent was obtained from both parents of each infant.
Randomization, intervention, and compliance
After inclusion, infants were categorized according to the
atopic status of the father (as the main prognostic factor in addi-
tion to the mother’s atopy) and then randomly assigned to the
experimental or placebo group with the use of block randomiza-
tion in blocks of 4. Intervention started as soon as possible after
baseline blood sampling at the age of 7 ± 2 d, or 14 d at the latest.
The supplementation period ended when the infant reached the
age of 6 mo. The intervention comprised a daily supplement, given
as 1 g powder and consisting of fish gelatin (135 mg), maltodex-
trin (397 mg), silicic acid (21 mg), and oil (446 mg). The oil was
either borage oil (Borago officinalis, verum) or sunflower oil
(placebo), which closely resembled borage oil with respect to fatty
acid composition, except that the GLA in verum was replaced by
oleic acid (18:1n9) (Table 1). Both supplements contained vita-
mins C and E as antioxidants, and they were provided by Hoff-
mann-La Roche (Basel, Switzerland). The powders were packaged
in low-oxygen sachets to blind the investigators and parents to
possible differences in their smell and appearance. So that the sup-
plement would be distributed evenly throughout the day, parents
were instructed to put the supplement in the total amount of for-
mula made for 1 d. The dose was chosen to reflect upper normal
concentrations of GLA in human milk. Mean GLA concentrations
reported for human milk [as percentages by weight (wt%) of total
milk lipids] in Western populations vary from 0.07wt% (9) to
0.35wt% (15). Other studies reviewed by Jensen (1992) showed
concentrations between these values (13). We aimed for the high-
est concentration, 0.35wt%, of GLA in human milk. At a total typ-
ical daily output of 750 g milk with 4wt% total fat, this amounts
to < 100 mg GLA/d. The actual amount of GLA present in the
GLA supplement was 23.1% of the 446 mg of borage oil in a daily
dose, ie, 103 mg GLA/d.
Compliance was measured by counting the number of sachets
returned. Mothers were instructed to keep a diary focusing on
events that disturbed the infants’ food or supplement intake. Com-
pliance was considered to be complete if ≥ 85% of the sachets had
been used during the entire supplementation period. We expected
that the rise in plasma GLA would reflect compliance on the basis
of earlier supplementation studies (13), and therefore we meas-
ured the rise in plasma GLA from baseline (before supplementa-
tion) up to 3 and 6 mo.
Sampling and laboratory analyses
Blood was collected from the women by venipuncture of the
median cubital vein at 34–36 wk of gestation and from the infants
at the ages of 1 wk, 3 mo, and 6 mo by heel prick or finger prick
and at the age of 1 y by venipuncture of the hand vein or of the
median cubital vein. Blood was collected in tubes containing
EDTA (Becton Dickinson, Orangeburg, NJ) and in serum-separa-
tor tubes (Sherwood-Davis & Geck, St Louis). The samples were
transported on an ice-and-water mixture and, within 24 h after col-
lection, centrifuged at 3000  g for 10 min at 4 C and stored at
20 C (serum) or 50 C (plasma) under nitrogen until analysis.
If an insufficient amount of venous blood was acquired, finger
prick blood was collected on blotting paper for total serum
immunoglobulin E (IgE) analysis.
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Fatty acids were analyzed as previously described (16). Lipid
extracts were prepared from plasma samples, and phospholipid
fractions separated using aminopropyl-bonded phase columns
(17). Phospholipids were hydrolyzed and fatty acids were trans-
methylated with boron trifluoride (Sigma Chemical Co, St Louis)
in methanol. The composition of the fatty acid methyl esters
obtained was determined by capillary gas chromatography with
the use of a polar capillary column (CPSil 88; Chrompack, Mid-
delburg, Netherlands) and with helium as the carrier gas. The
amount of each fatty acid was quantified by adding an internal
standard [dinonadecanoyl (19:0)-phosphatidylcholine; Sigma
Chemical Co]. Results are reported as wt% of total fatty acids,
computed as previously described (18).
Screening tests for total IgE and for common aeroallergens and
food allergens (Phadiatop and Fx5, respectively) were performed in
serum from infants at age 1 y with the use of a new in vitro test sys-
tem (UniCAP; Pharmacia Upjohn, Uppsala, Sweden) as described
elsewhere (19). Measurement of total IgE in eluted blood spot mate-
rial was performed in a sandwich assay, as previously described
(20), with minor modifications: a mixture of anti-human IgE mono-
clonal antibodies was coupled to Sepharose 4B (Pharmacia Upjohn)
to bind IgE; Sepharose-bound IgE was detected with the use of radi-
olabeled antibodies against human IgE, raised in sheep.
Clinical outcome variables and adverse events
At the follow-up hospital visit when the infants were age 1 y, a
trained dermatologist (CH) made the clinical diagnosis ofAD by using
the criteria of the UK Working Party (21, 22). Briefly, the probability
of the presence of AD was derived from the presence of 4 clinical
symptoms: (1 the presence of itchy rash (PIR; coded as 1 = present,
0 = absent), (2 a history of flexural dermatitis (HFD; 1 = present, 0 =
absent), (3 visible flexural dermatitis (VFD; 1 = present, 0 = absent),
and (4 onset before 2 y of age (OB2; 1 = present, 0 = absent). HFD
and VFD were modified to the extensor side of the limbs to match the
typical clinical predilection sites in infants (21, 22). The UK Work-
ing Party probability score for AD was then computed as
Probability (AD) = odds (AD)/[odds (AD) + 1] (1)
where odds (AD) = exp[4.86 + 1.84(HFD) + 3.46(OB2) +
2.09(VFD) + 1.71(PIR)] (21, 22). In the present study, infants with
a > 0.50 probability of AD were considered to have AD.
Severity of dermatitis was scored by one dermatologist (CH)
using clinical criteria (SCORing Atopic Dermatitis; SCORAD; 23,
24). These criteria include measuring the size of the affected area
(A) and scoring the intensity of the dermatitis (B), with 5 criteria
for scoring intensity: erythema, edema or papulation, oozing or
crusting, excoriation, and lichenification (each with scores 0–2).
The SCORAD index was computed as A/5 + (7  B)/2 (23, 24).
At the same time, the SCORAD index was obtained independ-
ently by one of the other trained investigators (CJAWvG or CT) to
assess interobserver variability with the dermatologist. Parents
were asked to report on the severity of itch and on sleeplessness
as a result of itch, with the use of a visual analogue scale ranging
from 0 (smiling baby) to 100 (crying baby). Parents were also
asked to bring the infants’ medication to the hospital, and the use
of emollients and corticosteroids was carefully noted.
Size of the study population
The reported incidence of AD in the first year of life ranged
from 22–33% (25) to 38% (26), with a mean of 35.5%, in breast-
fed infants at risk and from 49% (25) to 57% (27), with a mean of
53%, in formula-fed infants. Several studies have reported a
stronger maternal than paternal inheritance; the only study to
report incidences separately for atopic mothers and atopic fathers
found a 47% incidence of atopic eczema in children with atopic
mothers and a 10% incidence in children with atopic fathers (28).
Assuming an average AD incidence of 53% in the placebo
group, we aimed at a 41% risk reduction in the intervention group
(which would equal an incidence of 31%, equivalent to the inci-
dence in breast-fed infants). For a power of 80% (at  = 0.05; one-
sided), the study size needed to detect this risk reduction was cal-
culated to be 122 infants.
Statistical analysis
Statistical analyses were performed with SPSS for WINDOWS
software, version 10.0 (SPSS, Inc, Chicago). AD was the main out-
come variable, with SCORAD index and total and specific IgE con-
centrations as secondary outcome measures. Total serum IgE was
not normally distributed and was therefore transformed to its natu-
ral logarithm (log IgE). Spearman’s rank correlations were calcu-
lated to assess the correlation between the different outcome vari-
ables (SCORAD, log IgE, and UK Working Party probability score).
In the intention-to-treat analysis comparing GLA and placebo
groups for binary outcome measures (AD, reported itch, topical
steroid use, emollient use, and positive Fx5), odds ratios were
computed with the use of logistic regression analysis. Differences
in mean SCORAD and log IgE between the GLA and placebo
groups were tested for significance by the use of Student’s t test
( = 0.05, two-sided) or analysis of covariance when corrected for
covariables; 95% CIs are reported throughout.
In the explanatory analysis with an increase in plasma GLA as
a marker of compliance, logistic regression analysis was per-
formed to test the association between the increase in the infant’s
plasma phospholipid GLA concentration from the age of 1 wk
(baseline) to 3 mo and from the age of 1 wk to 6 mo and the inci-
dence (or nonincidence) of AD. Because the SCORAD index was
not distributed normally and log transformation did not overcome
this problem, logistic regression analysis was also used to test the
association between the higher and lower tertiles of the SCORAD
index and the rise in GLA. Linear regression analysis was used to
investigate the relation between log IgE at the age of 1 y and the
rise in GLA; in addition, we performed logistic regression analy-
sis with the higher and lower tertiles of IgE as the outcome.
Potential confounders included as covariates in the multivariate
logistic regression models were variables that are known to be
associated with atopy: the atopic status of the father, smoking dur-
ing pregnancy, smoking by parents in the first year of the infant’s
life, the age of the mother at delivery, the infant’s sex, the total
serum IgE of the infant at 1 wk, the total serum IgE of the mother,
the number of siblings, day-care attendance, the educational level
of the father, the educational level of the mother, the presence of
a dog in the household, the presence of a cat in the household, and
the use of allergen-free bed covers.
RESULTS
One hundred twenty-one infants were included in the study. At
the age of 1 y, 118 infants had completed follow-up, 58 in the GLA
group and 60 in the placebo group (Figure 1). The other 3 infants
did not complete the supplementation and were lost to follow-up.
Complete compliance (> 85% of the sachets used) was observed
in 85% of the infants (51 in the GLA group and 51 in the placebo
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FIGURE 1. Trial profile: follow-up, compliance, and reported adverse
events in the study (EFAtop study).
TABLE 2
Baseline variables and co-interventions between the -linolenic acid
(GLA) and placebo groups1
GLA group Placebo group
(n = 60) (n = 58)
Family history
Atopic history of mother
Asthma (n) 27 26
Rhinitis (n) 51 43
Atopic eczema (n) 23 20
Positive allergen test (n) 47 41
Use of antihistamine drugs (n) 23 20
Total serum IgE of mother (n in tertiles)2
1–52 (kU/L) 21 18
53–209 (kU/L) 22 17
210–5506 (kU/L) 17 23
Positive aeroallergen screening test in 44 46 
mother (n)
Positive food allergen screening test in 9 9 
mother (n)
Atopic history of father (n)
Positive 22 21
Uncertain or negative 38 37
Age of mother at time of delivery (y) 31.2 ± 4.03 30.5 ± 3.9
Duration of pregnancy (wk) 40.1 ± 1.3 40.1 ± 1.1
Child
Girls (%) 55 53
Birth weight (g) 3513 ± 483 3528 ± 463
Birth length (cm) 50.6 ± 2.5 49.9 ± 2.5
Head circumference at birth (cm) 34.9 ± 1.6 34.8 ± 1.4
Total serum IgE in infants at age 1 wk 
(n in tertiles)2
0.00–0.10 (kU/L) 23 16
0.11–0.73 (kU/L) 19 20
0.74–21.00 (kU/L) 16 21
Risk factors
Highest educational level of either 
parent (n)
Low 4 8
Middle 34 30
High 22 20
Number of siblings (n)
0 27 30
1 22 19
2 or more 11 9
Day-care attendance (d/wk) 0.92 ± 1.06 1.04 ± 1.13
Pets present in the house (n)
Cat 5 2
Dog 19 17
Rabbit 2 2
Carpet in living room (n) 6 5
Carpet in infant’s bedroom (n) 144 3
Allergen-free cover on infant’s bed (n) 2 6
1 IgE, immunoglobulin E.
2 Tertiles based on total cohort (GLA and placebo groups), with one
subject missing in the placebo group.
3 x– ± SD.
4 Significantly different from placebo group, P < 0.007 (Fisher’s exact test).
group). Five infants in each group had used 50–85% of the sachets
(semicompliers), whereas 4 infants in the GLA group and 2 infants
in the placebo group had used < 50% (noncompliers) (Figure 1).
Adverse events were equally divided between the GLA and placebo
groups all 121 infants, with abdominal cramps (3 infants) and bringing
up milk (5 infants) being the most frequent symptoms (Figure 1). Both
symptoms were usually temporary, but in most cases they resulted in the
supplements being withheld from the infant by the parents for 2 d to
2 wk, to ensure that the symptoms were not caused by the supplements.
When the symptoms subsided, parents were asked to reintroduce the
supplement slowly and to report whether the problems recurred.
The GLA and placebo groups did not differ significantly with
regard to baseline variables except for the presence of a carpet in the
bedroom of more of the infants in the GLA group than of those in the
placebo group (Table 2). In our population, the ratio of LA to ALA in
infant formulas was between 10:1 and 6:1, and the formulas contained
no LCPs. The course of GLA, DGLA, and AA concentrations in the
infants’ plasma phospholipids for the GLA and placebo groups is
shown in Figure 2. At 3 mo, the concentrations of GLA, DGLA, and
AA were, respectively, 70%, 24%, and 13% higher in the GLA group
infants than in the placebo group infants. At 6 mo, the concentrations
of GLA, DGLA, and AA were, respectively, 47%, 19%, and 15%
higher in the GLA group infants than in the placebo group infants.
When corrected for baseline concentrations (at 1 wk), all these differ-
ences remained significantly different. In the GLA group, compliers
had distinctly higher GLA, DGLA, and AA concentrations at 3 and 6
mo than did compliers in the placebo group, whereas semicompliers
and noncompliers in the GLA group had concentrations similar to
those of semicompliers and noncompliers in the placebo group.
The Spearman’s rank correlation between the UK Working
Party probability score and SCORAD index was 0.56 (P = 0.01).
There was no correlation between the UK Working Party proba-
bility score and log total serum IgE (r = 0.12, P = 0.21) or between
the SCORAD index and log total serum IgE (r = 0.09, P = 0.29).
We defined AD by dichotomizing the UK Working Party prob-
ability score into a low score (ie, 0.29, meaning “AD absent”;
67 infants) and high scores (probability 0.69–0.95, meaning “AD
present”; 51 infants).
In the intention-to-treat analyses (Table 3), infants in the GLA
group showed a trend toward lower SCORAD values (P = 0.09;
P = 0.06 after adjustment for total serum IgE at baseline). In con-
trast, the GLA group showed a tendency toward higher total serum
IgE values than did the placebo group. When the analyses were
restricted to the compliers, the differences for SCORAD values
remained roughly the same (Table 4). IgE or positivity on the food
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FIGURE 2. Mean (± SEM) -linolenic acid (GLA), dihomo--linolenic acid (DGLA), and arachidonic acid (AA) concentrations in infants’ plasma
phospholipids in the GLA group and the placebo group. Total GLA group, all infants randomly assigned to receive GLA supplementation (n = 58); placebo
group (n = 60); GLA compliers, infants in the GLA group who complied with the treatment (n = 51); GLA semicompliers and noncompliers, infants in the
GLA group who partially complied (semicompliers; n = 5) or did not comply (noncompliers; n = 4). Values were missing for 3 GLA compliers at 1 wk and
for 2 infants in the placebo group at 3 mo. Significance of differences between the total GLA group and the placebo group by analysis of covariance: aP <
0.001 after adjustment for baseline concentrations at 1 wk; bP < 0.01 after adjustment for baseline concentrations at 1 wk.
TABLE 3
Atopic outcomes at age 1 y in infants randomly assigned to receive -linolenic acid (GLA) or placebo supplementation in intention-to-treat analysis1
GLA group Placebo group Adjusted OR2
(n = 60) (n = 58) OR (95% CI) P (95% CI) P
Atopic dermatitis, UK Working Party probability 23 28 0.67 (0.32, 1.39) 0.28 0.69 (0.33, 1.45) 0.33 
score > 0.50 (n)
Parent reported itch (n) 3 7 0.38 (0.09 – 1.56) 0.18 0.33 (0.08, 1.39) 0.13
Severity of atopic dermatitis (SCORAD index)3,4 6.32 ± 5.32 8.28 ± 6.54 0.09 0.06
Topical steroid use, class 1 or 2 (n) 2 (1, 1) 5 (4, 1) 0.37 (0.68, 1.96) 0.24 0.41 (0.08, 2.23) 0.30
Emollient use (n) 27 21 1.44 (0.39, 3.02) 0.33 1.37 (0.64, 2.92) 0.42
Total serum IgE at age 1 y5,6 9.31 ± 4.45 6.87 ± 3.56 0.24 0.10
Positive food allergen test (n) 10 (2 missing) 5 (4 missing) 2.04 (0.65, 6.92) 0.22 2.32 (0.72, 7.46) 0.16
1 OR, odds ratio; SCORAD, SCORing Atopic Dermatitis; IgE, immunoglobulin E.
2 Adjusted for total serum IgE at baseline (age 1 wk).
3 Differences of the means between GLA group and placebo group, 1.90 (95% CIs: 4.07, 0.27); P = 0.09 (Student’s t test). Differences of the means
between GLA group and placebo group corrected for baseline IgE (at 1 wk), 2.16 (95% CIs: 4.38, 0.06); P = 0.06 (analysis of covariance).
4 x– ± SD.
5 Differences of the geometric means of total serum IgE between GLA and placebo groups, 1.36 (95% CIs: 0.82, 2.25); P = 0.24 (Student’s t test). Dif-
ferences of the geometric means of total serum IgE between GLA and placebo groups, corrected for baseline IgE (at 1 wk), 1.54 (95% CIs: 0.92, 2.56);
P = 0.10 (analysis of covariance).
6 Geometric x– ± SD.
allergens screening test did not differ significantly between the
GLA and the placebo groups. None of the infants had a positive
Phadiatop aeroallergen screening test.
In the explanatory analysis with the increase in plasma GLA as
a marker of compliance, that from baseline to 3 mo of age was
negatively and significantly associated with the SCORAD index at
1 y of age (Tables 5 and 6). The odds ratios for this association
were insensitive for the cutoff value of SCORAD (between 0.36
and 0.39) and were even slightly lower (0.27 and 0.29) after
adjustment for possible confounding factors. No such associations
were found for AD or total serum IgE (Table 5). The increase in
plasma GLA concentration from baseline to 6 mo was not related
to any of the atopic outcomes.
Because the association between GLA increase and SCORAD
value could be biased (being based on an explanatory analysis), it
may be subjected to protopathic bias. This bias exists when an
early (protopathic) stage of disease or an underlying etiologic con-
dition leads to changes in the risk factor, which produce a spuri-
ous association between the risk factor and the disease (29). In the
EFAtop study, this bias may have occurred for the following reasons:
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TABLE 4
Atopic outcomes at age 1 y in infants randomly assigned to receive -linolenic acid (GLA) or placebo supplementation (compliers only)1
GLA group Placebo group Adjusted OR2
(n = 51) (n = 51) OR (95% CI) P (95% CI) P
Atopic dermatitis, UK Working Party probability 19 22 0.78 (0.35, 1.73) 0.54 0.81 (0.36, 1.82) 0.61 
score > 0.50 (n)
Parent reported itch (n) 3 5 0.58 (0.13, 2.55) 0.47 0.50 (0.11, 2.30) 0.37
Severity of atopic dermatitis (SCORAD index)3,4 6.07 ± 5.16 7.92 ± 6.26 0.11 0.06
Topical steroid use, class 1 or 2 (n) 1 (1, 0) 4 (4, 0) 0.24 (0.03, 2.18) 0.20 0.24 (0.03, 2.24) 0.21
Emollient use (n) 24 17 1.78 (0.80, 3.96) 0.16 1.68 (0.73, 3.86) 0.22
Total serum IgE at age 1 y5,6 7.9 ± 4.3 6.9 ± 3.7 0.67 0.34
Positive food allergen test (n) 8 (0 missing) 4 (4 missing) 2.05 (0.57, 7.32) 0.27 2.48 (0.67, 9.16) 0.87
1 OR, odds ratio; SCORAD, SCORing Atopic Dermatitis; IgE, immunoglobulin E.
2 Adjusted for total serum IgE at baseline (age 1 wk).
3 Differences of the means between GLA group and placebo group, 1.84 (95% CIs: 4.09, 0.41); P = 0.11 (Student’s t test). Differences of the means
between GLA group and placebo group corrected for baseline IgE (at 1 wk), 2.25 (95% CIs: 4.57, 0.08); P = 0.06 (analysis of covariance).
4 x– ± SD.
5 Differences of the geometric means of total serum IgE between GLA and placebo groups, 1.12 (95% CIs: 0.65, 1.93); P = 0.67 (Student’s t test). Dif-
ferences of the geometric means of total serum IgE between GLA and placebo groups, corrected for baseline IgE (at 1 wk), 1.31 (95% CIs: 0.99, 1.25);
P = 0.34 (analysis of covariance).
6 Geometric x– ± SD.
TABLE 5
Association between the increase in plasma phospholipid -linolenic acid (GLA) concentration and atopic outcomes at age 1 y1
Increase in GLA between 1 wk and 3 mo2 Increase in GLA between 1 wk and 6 mo3
Crude OR Adjusted OR Crude OR Adjusted OR
(95% CI) (95% CI)4 (95% CI) (95% CI)4
Atopic dermatitis5
Present (n = 51) compared with absent (n = 67) 0.81 (0.40, 1.65) 1.11 (0.47, 2.65) 0.94 (0.57, 1.55) 1.25 (0.66, 2.40)
SCORAD index6
High+middle (n = 81) compared with low (n = 37) tertile 0.36 (0.15, 0.87) 0.27 (0.09, 0.86) 0.78 (0.44, 1.38) 0.70 (0.31, 1.54)
High (n = 38) compared with low+middle (n = 80) tertile 0.39 (0.17, 0.89) 0.29 (0.09, 0.90) 0.68 (0.39, 1.17) 0.71 (0.34, 1.47)
Total serum IgE7
Middle+high (n = 79) compared with low (n = 39) tertile 1.29 (0.62, 2.70) 1.44 (0.57, 3.60) 1.18 (0.70, 2.00) 1.20 (0.63, 2.29)
High (n = 40) compared with low+middle (n = 78) tertile 1.02 (0.49, 2.14) 1.36 (0.52, 3.54) 1.18 (0.68, 2.06) 1.14 (0.58, 2.24)
1 SCORAD, SCORing Atopic Dermatitis; IgE, immunoglobulin E.
2 Five values missing (SCORAD index: 4 in middle category and 1 in high category; IgE: 2 in low category, 1 in middle category, and 2 in high category).
3 Three values missing (SCORAD index: 2 in middle category and 1 in high category; IgE: 1 in low category and 2 in high category).
4 Covariables included in the multivariate logistic regression model were atopic status of father, smoking during pregnancy, smoking by parents in the
infants’ first year, age of mother at time of delivery, sex of infant, IgE of infant at 1 wk, IgE of the mother, number of siblings, day-care attendance, educa-
tional level of the father, educational level of the mother, presence of dog, presence of cat, and use of allergen-free bed covers.
5 Present if UK Working Party probability score was > 0.50.
6 SCORAD index range, 0–30.3 divided into tertiles (cutoffs were 4.1 and 8.7).
7 Range, 1.00–371 kU/L divided into tertiles (cutoffs were 4.00 and 12.40 kU/L).
(1 a genetic atopic constitution is truly associated with a later high
SCORAD index and forms the underlying condition; (2 an atopic
constitution increases the risk of food allergy in the first few
months of life, and this is associated with feeding problems; and
(3 these feeding problems may lead to difficulty with the use of
the supplement, as indicated by noncompliance or suboptimal
compliance. The resulting lower intake of GLA is reflected in fail-
ure to show an increase in plasma concentrations of GLA. In this
way, a negative association between the increase in GLA and the
SCORAD index is produced, even if there is no true effect on the
SCORAD index. We scrutinized the data in search of typical cases
of infants who fulfilled these conditions for protopathic bias. As
indicative of feeding problems related to food allergy, we selected
infants who were switched to hypoallergenic formula, were sus-
pected by the parents of having a food allergy, or had a positive
food allergen test and infants who had feeding problems or were
known as noncompliers. We evaluated in these infants whether the
SCORAD index was particularly high (as a consequence of the
underlying atopic condition) and, if so, whether the GLA increase
was indeed low (as a consequence of possible noncompliance due
to early atopic symptoms). This was done only for infants in the
group receiving verum, because only in this group does supple-
mentation lead to GLA increase. We identified only 2 infants who
fulfilled the conditions for protopathic bias. Even so, the SCORAD
index in those infants was in the middle range (4.3–7.4), and thus
the impact on the results of the group as a whole is quite limited,
which leads us to conclude that protopathic bias is not likely.
DISCUSSION
As far as we know, this is the first published preventive trial of
GLA supplementation on AD; earlier trials have been therapeutic,
aiming at the improvement of existing AD. Results of these ther-
apeutic trials have been inconsistent (30, 31). Some of the trials
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TABLE 6
Association between the increase in plasma phospholipid -linolenic acid (GLA) concentration between age 1 wk and 3 mo and SCORAD index at age 1 y1
GLA increase between age 1 wk and 3 mo (tertiles)
SCORAD index at Low tertile Middle tertile High tertile
age 1 y (tertiles) (0.216 to 0.004 wt%) (0.005–0.040 wt%) (0.041–0.179 wt%) Total
Low tertile (0–4.1) 7 10 17 34
Middle tertile (4.2–8.6) 12 17 13 42
High tertile (8.7–30.3) 18 12 7 37
Total 37 39 37 11
1 SCORAD, SCORing Atopic Dermatitis. Spearman’s correlation coefficient, 0.233; P = 0.013. Linear-by-linear association, P = 0.002.
had methodologic drawbacks such as heterogeneity of the study
population in terms of age (32) or the unblinded status of either
the subjects or the investigators (33). Among 4 trials in children
with AD, 3 showed no greater effect of GLA than of placebo (11,
34, 35), and only 1 (10) showed a favorable effect on the severity
of eczema of GLA compared with placebo. Our study was
designed to investigate the possible protective role of GLA in the
development of atopic dermatitis in infants with atopic mothers.
On the basis of an intention-to-treat analysis, we observed a
trend for severity of dermatitis (as measured by the SCORAD
index) in the GLA group that was favorable but not significantly
different from that in the placebo group. The effects of GLA sup-
plementation on another clinical atopic outcome (ie, itch) trended
similarly but were not significant.
When the increase in plasma phospholipid GLA was used as
a marker of compliance, the severity of AD as measured by the
SCORAD index had a strongly negative association with the
increase in GLA in infants aged 1 wk–3 mo. Apart from being
a marker of compliance, the increase in GLA also incorporates
the effect of intestinal uptake of GLA. Because this was not an
intention-to-treat analysis, it is important to check for biases.
First, selective follow-up was not likely to occur because all but
3 children completed the follow-up. Second, information bias
was unlikely because the investigator, the patient, and the out-
come assessor remained blinded for the allocation of the sup-
plements and for GLA concentrations in the infants. Third, data
were checked for protopathic bias, which was ruled out. Fourth,
when we controlled for possible confounding factors in the
analyses of plasma GLA increase and SCORAD, the association
remained as strong and significant. We therefore think that the
association is real. However, our results are not definite proof of
a causal effect of supplementation. They could also be explained
by a metabolic difference in EFA metabolism between infants
with and without an atopic constitution, which occurs only after
GLA supplementation, but this explanation does not fit any of
the current hypotheses. No associations were observed between
the increase in GLA and the presence or absence of AD or the
total serum IgE concentration.
If there is a causal effect of GLA supplementation on the sever-
ity of AD, the observation that the clearest results are related to
the GLA concentrations in the plasma of infants at age 3 mo
would suggest that the constant dose of GLA given over time in
this study might not be sufficient with progressing age and
increasing body weight. It is therefore possible that the effect of
GLA would be more pronounced with a higher dose of GLA at a
later age. Another explanation for these findings might be that this
early period represents the time frame within which the immune
system is most susceptible to GLA. That would be consistent with
the results of Galli et al (6), who showed that the concentrations
of n6 LCPs were consistently and significantly lower in umbil-
ical cord blood and in serum at 1 and 3 mo of age in infants who
developed atopy at the age of 1 y than in infants who remained
unaffected, and that, in infants aged 1 y, these differences in n6
LCP concentrations were no longer present.
Our study shows an effect of GLA on the severity of AD but
not on the development of IgE at the age of 1 y. This indicates
that GLA supplementation has a beneficial effect on the inflam-
matory component of AD, rather than on its IgE-mediated com-
ponent. The absence of a correlation between clinical outcome
measures (incidence of AD and SCORAD index) and total and
specific IgE in the present study also indicates that different com-
ponents are implicated in the pathogenesis of AD. For a similar
reason, it has recently been proposed to revise the nomenclature
of AD and to refer to the condition as atopic eczema and der-
matitis syndrome (AEDS) (36), which would include IgE-mediated
and non-IgE-mediated pathogenesis. The heterogeneity of
patients in terms of AEDS between the previous therapeutic stud-
ies might partially explain the inconsistent results of GLA sup-
plementation in those studies.
The beneficial effect of GLA supplementation on the severity
of AEDS can be explained by the results of in vitro studies on skin
epidermis (37, 38). Normal skin epidermis is unable to convert
LA into GLA. Dietary GLA is actively converted into DGLA in
guinea pig epidermis (39), a model believed to resemble human
epidermis. Because 5-desaturase (EC 1.14.99.-), which converts
DGLA into AA, is absent from skin epidermis, the increase in
DGLA in the skin as result of, for instance, GLA supplementation
will not result in an increase in AA and prostaglandin E2 in the
skin. As a result, feeding humans a diet high in GLA raises
prostaglandin E1 and 15-hydroxy-eicosatrienoic acid concentra-
tions (40). Both prostaglandin E1 and 15-hydroxy-eicosatrienoic
acid have antiinflammatory properties (37).
We found a slightly but significantly higher concentration of
AA at 3 and 6 mo of age in the GLA group infants than in the
placebo group infants. Because metabolites of AA are known to
exert potent proinflammatory effects, a higher concentration can
enhance inflammation (1). However, the results suggest that this
is not the case, given the positive effects on the association of the
SCORAD index with the increase in the plasma GLA concentra-
tion. The metabolic products of GLA and DGLA, prostaglandin
E1 and 15-hydroxy-eicosatrienoic acid, have apparently been pro-
duced in sufficient amounts to inhibit the formation of these AA
metabolites (40).
Other studies provide additional explanations for the possible
beneficial effects of EFAs on skin epidermis. Dry skin and itch
are typical of patients with AD, and dry skin correlates with a dis-
turbed epidermal barrier function (41). It has been shown that LA
in particular is required for the formation and maintenance of the
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epidermal barrier (42, 43). In addition, topically applied evening
primrose oil has yielded positive results in stabilizing the stratus
corneum barrier (44), and the most pronounced positive effect
attributed to GLA in supplementation studies has been the reduc-
tion of itch (45–48). Besides the antiinflammatory effects of GLA
on skin epidermis, it might play a physical structural role in the
stability of the skin. Many of the immunologic changes associated
with GLA supplementation have been attributed to alterations in
GLA metabolites that in turn down-regulate the production of AA-
derived leukotrienes (1). For instance, Ziboh and Fletcher (40)
showed that GLA inhibits leukotriene B4 in a dose-dependent
way. The highest GLA dose in that study was quite similar to the
dose used in our study (1500 mg GLA/d approximates
21 mg · kg1 · d1 for adults weighing 70 kg; 103 mg GLA/d in
our study approximates 19 mg · kg1 · d1 for infants weighing
5.5 kg at age 3 mo). We found a similar dose-response relation.
Therefore, we think that the results of Ziboh and Fletcher support
our findings. However, to assess a cause-and-effect relation, future
preventive trials with GLA supplementation should also focus on
defining changes in the metabolites involved in AD.
In conclusion, the results show that early supplementation with
GLA does not prevent the expression of atopy as reflected by total
serum IgE, but that it does tend to alleviate the severity of AD in
later infancy in children at high familial risk. Future studies should
distinguish between atopic (IgE-mediated) and inflammatory
components of AEDS.
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